Industry Insights: Retina Practices Seek Transparency and Strategic GPO Partnerships

Overview

Retina practices face challenges with specialty drug management including rising costs, operational inefficiencies, and opaque pricing. They desire GPO and specialty distributor partners who provide transparency, strategic guidance, and technology-driven solutions to optimize drug procurement and financial performance.

Background

The specialty drug landscape for retina practices is increasingly complex due to rising drug costs, biosimilar alternatives, payer pressures, and operational challenges. Group purchasing organizations (GPOs) and specialty distributors (SDs) play a critical role in helping practices manage these complexities. However, many retina practices report frustrations with unclear pricing, manual inventory processes, and lack of strategic support. Emerging biosimilars and shifting payer dynamics further complicate procurement decisions, necessitating smarter, more flexible partnerships.

Data Highlights

Practices reported key operational and financial concerns including: excess inventory tying up working capital, delays from step therapy and prior authorizations, manual reconciliation of inventory and revenue data, slow rebate payments, and limited visibility into net cost recovery. They emphasized the need for predictive drug management systems, automation, and comprehensive analytics to measure the full financial lifecycle of each vial.

Key Findings

• Opaque pricing structures and slow rebate payments cause frustration and reduce trust in GPO and SD partnerships.
• Manual reconciliation across EMR, inventory, and revenue systems wastes staff time and increases errors.
• Practices want strategic guidance and education to navigate biosimilars and changing payer environments, not just product delivery.
• Concerns exist about long-term contracts, conflicts of interest, and maintaining practice independence.
• Successful partnerships are built on flexibility, transparency, innovation, and trustworthy, hands-on support.
• Essential analytics include visibility into drug usage, inventory levels, rebate timelines, and true net costs to optimize financial performance.

Clinical Implications

Retina practices should seek GPO and specialty distributor partners who offer transparent pricing, flexible contract terms, and integrated technology solutions to reduce administrative burden. Strategic collaboration and data-driven insights can help practices adapt to evolving drug options and payer requirements, ultimately improving operational efficiency and financial sustainability.

Conclusion

As the specialty drug environment evolves, retina practices benefit most from GPO and SD partnerships that prioritize transparency, strategic support, and innovation. Such collaborations enable practices to maintain autonomy, optimize drug management, and enhance patient care.

References

1. Denning & Waters, AllyGPO/BioCareSD, 2025 -- Industry Insights: Inventory to Impact